



Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients

K. Westerdijk¹ · S. D. Krens^{2,3} · N. Steeghs⁴ · W. T. A. van der Graaf^{4,5} · E. T. T. L. Tjwa⁶ · H. Westdorp¹ · I. M. E. Desar¹ · N. P. van Erp²

Received: 18 August 2023 / Accepted: 3 November 2023 / Published online: 17 December 2023

© The Author(s) 2023

Abstract

Purpose Pazopanib is known to cause liver toxicity. A relationship between pazopanib exposure and alanine transaminase elevations has been described in clinical trials. This study investigated the relation between pazopanib exposure and liver toxicity in real-world patients and evaluated the management of pazopanib-induced liver toxicity in routine care.

Methods A retrospective observational cohort study was performed in patients treated with pazopanib in whom pazopanib exposure was measured. The percentage of patients with and without liver toxicity during treatment with pazopanib was calculated as well as the average pazopanib exposure in both groups. Furthermore, the management of patients with liver toxicity was evaluated.

Results Liver toxicity was observed in 25 out of the 133 patients included (19%). Pazopanib exposure was comparable in patients with or without liver toxicity (27.7 mg/L versus 28.1 mg/L). Seven patients permanently discontinued pazopanib after the occurrence of liver toxicity. Of the remaining 18 patients, continuation or restart of pazopanib after liver toxicity was successful in 16 patients and half of these patients were able to safely continue pazopanib at the same dose as prior to liver toxicity for the remaining duration of treatment.

Conclusion Our study did not demonstrate a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity. Half of the patients were able to safely continue or restart pazopanib treatment after liver toxicity and received the same dose as prior to drug withdrawal. Successful interventions to address pazopanib-induced toxicity in the clinic led to an algorithm for the management of pazopanib-induced liver toxicity.

Keywords Pazopanib · Liver toxicity · Drug-induced liver injury · Therapeutic drug monitoring · Prednisolone

K. Westerdijk and S. D. Krens shared first author.

✉ K. Westerdijk
kim.westerdijk@radboudumc.nl

¹ Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, P.O. Box 9101, Nijmegen, The Netherlands

² Department of Clinical Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands

³ Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

⁴ Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

⁵ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands

⁶ Department of Gastroenterology and Hepatology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands

Introduction

Pazopanib is an oral tyrosine kinase inhibitor (TKI) registered for the treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) [1, 2]. It targets multiple kinase receptors, including vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR1-3), platelet-derived growth factor receptor α and β (PDGFR α - β) and cytokine receptor (KIT) [3].

Many drugs can cause drug-induced liver injury (DILI) [4, 5]. DILI is classified as either direct or indirect [6]. Direct DILI is the result of a direct effect of the drug or its metabolites on the hepatocytes. An example of a drug that causes direct DILI is acetaminophen where the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI) causes liver injury [7]. Indirect DILI is less predictable and occurs in a fraction of patients using the drug [8, 9]. DILI can vary from asymptomatic elevation in liver enzymes to acute liver failure. Pazopanib has been reported to induce liver toxicity. The FDA label of pazopanib includes a black box warning for hepatotoxicity and recommends to monitor liver function before start, at week 3 and every other week thereafter during the first two months of treatment [10]. Elevations in serum alanine transaminase (ALT) and aspartate transaminase (AST) were observed in more than half of the patients in clinical trials, sometimes leading to severe and even fatal liver function disorders [1, 2, 10, 11].

The mechanism behind pazopanib-induced liver toxicity has not yet been elucidated [12]. It has been hypothesized that pazopanib reactive aldehyde metabolites could be responsible, or that liver toxicity is caused by inhibition of ATB binding cassette subfamily B member 11 (bile salt export pump) [13–15]. Furthermore, polymorphisms in the hemochromatosis gene (*HFE*) might be associated with ALT elevations [16]. Others suggest that polymorphisms in the gene uridine diphosphate glucuronosyltransferase 1A1 (*UGT1A1*), resulting in disorders with conjugation of bilirubin, adds to the risk of developing pazopanib-induced liver toxicity [17]. Pazopanib is a *UGT1A1* inhibitor and especially patients with Gilbert syndrome, caused by a polymorphism in *UGT1A1*, have an increased risk of hyperbilirubinemia with the use of pazopanib. Finally, it is hypothesized that pazopanib-induced liver toxicity might be caused by autoimmune inflammation which can be treated and prevented with corticosteroids [18–20].

The recommended starting dose of pazopanib is 800 mg OD taken fasted, while 600 mg OD taken with food leads to equivalent exposure [21]. Adequate exposure is essential since a clear exposure–response relationship has been shown [22–24]. As a result, Therapeutic Drug Monitoring (TDM) to individualize the dose is increasingly used to improve the benefit-risk balance in patients treated with

pazopanib. Especially for patients with STS, for whom treatment options are limited, it is important to continue pazopanib treatment for as long as possible. Suttle et al. demonstrated that patients with mRCC and a pazopanib trough concentration (C_{trough}) > 20.5 mg/L had a median progression free survival (PFS) of 52.0 weeks, compared to a median PFS of 19.6 weeks in patients with a pazopanib C_{trough} < 20.5 mg/L [22]. This observation was confirmed by Verheijen et al. [23]. While no clear cut-off level of pazopanib exposure for the development of toxicity has been described in literature, multiple studies do show a relationship between increased pazopanib exposure and adverse events, including liver enzyme changes [3, 22, 25]. The current label of pazopanib recommends to interrupt pazopanib treatment when liver enzymes increase > 8 \times upper limit of normal (ULN) and to restart pazopanib at a reduced dose of 400 mg OD (50%) upon normalization. Furthermore, if liver enzyme abnormalities persist or recur, permanent discontinuation of pazopanib treatment is recommended.

The occurrence of liver toxicity in patients treated with pazopanib and its relationship with pazopanib exposure has mainly been studied in registration studies, while clinical trial patients differ substantially from real-world patients [3, 22, 26]. Strict adherence to the current recommendations for the management of pazopanib-induced liver toxicity may interfere with optimal pazopanib exposure or even limit patient's treatment options. The primary aim of this study was to investigate the association between pazopanib exposure and the occurrence of liver toxicity in patients with solid tumors treated in routine care. The secondary aims were to evaluate the management of pazopanib-induced liver toxicity in routine care and to provide guidance for physicians.

Materials and methods

Patients

This observational study was performed using clinical data of patients with solid tumors who were treated with pazopanib and of whom at least one pazopanib trough level was available between March 2013 and February 2020. The current study was approved by the institutional review board at the Radboudumc and a waiver was granted for use of routine care data (dossier number 2018-4617).

Clinical data were collected from the electronic health records for all patients and included data on baseline characteristics (such as age, gender, body mass index (BMI) and performance status), diagnosis, disease stage, presence of liver metastases, laboratory investigations prior to the start of pazopanib, treatment with pazopanib (starting dose, dose

adjustments during treatment and whether pazopanib was administered with or without food) and potentially hepatotoxic co-medication (statins or acetaminophen). Furthermore, to assess the occurrence of liver toxicity and the association with pazopanib exposure, ALT, AST, bilirubin, serum albumin levels and pazopanib trough concentrations were collected from patient records after start of pazopanib treatment. Finally, data were collected on pazopanib treatment duration, whether treatment with pazopanib was interrupted due to the occurrence of liver toxicity, whether patients received corticosteroids for liver toxicity and the reason for stopping pazopanib treatment.

Assessment of liver toxicity

Liver toxicity was defined as ALT and/or AST $> 3 \times$ ULN (or $> 3 \times$ baseline level of normal (BLN) in case baseline was abnormal) on pazopanib treatment. This definition is based on the warning for liver toxicity in the FDA label of pazopanib and is equal to a grade 2 elevation according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute, version 5.0. Recovery was defined as a decline in ALT and/or AST $< 3 \times$ ULN (\leq grade 1 according to CTCAE). The percentage of patients with and without liver toxicity and the median time until the occurrence of liver toxicity was determined.

Pharmacokinetics

Pazopanib levels were measured in routine care. In routine care pazopanib levels are measured after reaching steady-state pharmacokinetics, on average ~ 4 weeks after start of treatment and thereafter at the discretion of the treating physician. Pazopanib plasma samples were collected 6 to 32 h after intake of pazopanib. C_{trough} levels were calculated using the approach of Wang et al. [27].

Pazopanib plasma concentrations were measured using a validated liquid chromatography tandem mass spectrometry assay comparable to the method earlier described by van Erp et al. [28].

Association between occurrence of liver toxicity and pazopanib exposure

In patients with liver toxicity the average pazopanib C_{trough} was calculated over 8 weeks prior to the occurrence of liver toxicity (details Supplemental Method 1). The median time until the occurrence of liver toxicity was taken as a reference interval for the patients without liver toxicity for whom the average pazopanib C_{trough} over 8 weeks until the median time was also calculated. The pazopanib C_{trough} were compared between patients with and without liver toxicity.

Furthermore, the pazopanib C_{trough} at the time of occurrence of liver toxicity in patients with liver toxicity was compared to average pazopanib C_{trough} in patients without liver toxicity.

According to the method used in the FDA pharmacology review, the association between pazopanib C_{trough} and the occurrence of ALT $> 5 \times$ ULN was determined [3].

For patients with liver toxicity who continued pazopanib treatment after the occurrence of liver toxicity, the median duration of pazopanib treatment after the development of liver toxicity was retrieved from the medical records. Also, the average pazopanib C_{trough} after the occurrence of liver toxicity was calculated for the remaining duration of treatment.

Association between occurrence of liver toxicity and survival

Patients were divided into two groups depending on the occurrence of liver toxicity (yes/no). Explorative analyses were performed between the occurrence of liver toxicity for PFS and overall survival (OS). PFS was defined as the time from start of pazopanib treatment until discontinuation or death due to progressive disease (PD). Patients who did not experience PD were censored at the date of pazopanib discontinuation due to other causes or the date of last follow-up. OS was defined as the time from start of pazopanib treatment until the date of death. In case patients were still alive at the time of database closure, they were censored at the date of last follow-up. The relationship between the occurrence of liver toxicity and PFS and OS were separately explored for RCC and STS.

Proposal for management of pazopanib-induced liver toxicity

As this was an observational study, management of pazopanib-induced liver toxicity was at the discretion of the treating physician. Based on pazopanib exposure data and clinical experiences, an algorithm for the treatment of pazopanib-induced liver toxicity for patients in routine care was developed.

Statistical analysis

Statistical analyses were performed using IBM SPSS statistics for Windows, version 27.0 (IBM Corp., Armonk, NY, USA). Patient characteristics, laboratory investigations at baseline, the occurrence and management of liver toxicity were described using descriptive statistics. Categorical variables were compared using the Chi-square test. Continuous variables that were not normally distributed were compared using the unpaired *T*-test on log-transformed data. Logistic regression was used to identify associations

between the patient characteristics age, BMI, performance status, tumor type, pre-treatment, pazopanib exposure, statin and acetaminophen use and the occurrence of liver toxicity ($ALT > 3 \times ULN$). Furthermore, the association between the occurrence of $ALT > 5 \times ULN$ and pazopanib C_{trough} was investigated using logistic regression, according to FDA analyses. Patient characteristics that were identified as predictors in univariate analysis were taken forward to multivariate analysis.

Pazopanib C_{trough} in patients with or without liver toxicity were compared using the unpaired *T*-test on log-transformed data.

PFS and OS were estimated with the Kaplan–Meier method and differences between patients with or without liver toxicity were examined with the log-rank test. Outcomes with a *P*-value less than 0.05 were considered statistically significant.

Results

Patients

Of the 133 patients included in this study, 25 (19%) met the definition of liver toxicity. Patient characteristics for both patients with or without liver toxicity are presented in Table 1. The median age was 62 (range 23–85) years and most patients were male (67%). A total of 98 patients were diagnosed with RCC, 33 patients with STS and 2 patients with gynaecological malignancies. Only albumin level was significantly different between both groups, though not clinically relevant. None of the patients who started pazopanib intake with food ($n = 18$) developed liver toxicity.

Development of liver toxicity

The median time until the occurrence of liver toxicity was 37 (interquartile range (IQR) 28–58) days. Seven patients (28%) had $ALT/AST 3–5 \times ULN$, 4 patients (16%) $ALT/AST 5–8 \times ULN$ and 14 patients (56%) $ALT/AST > 8 \times ULN$. Two of the patients with $ALT/AST > 8 \times ULN$ also had bilirubin level $> 2 \times ULN$.

The pazopanib dose at which liver toxicity occurred was 800 mg fasted in 18/25 patients (72.0%). The remaining patients received a dose of 800 mg with food (1/25, 4.0%), 600 mg fasted (3/25, 12.0%), 600 mg with food (1/25, 4.0%) or 400 mg fasted (2/25, 8.0%). In 18/25 patients (72%) the dose at which liver toxicity occurred was the same as the starting dose, 5 patients had a dose escalation based on a pazopanib $C_{trough} < 20.5$ mg/L prior to developing liver toxicity and 2 patients a dose reduction based on tolerability issues, being non-liver toxicity.

Association between pazopanib exposure and occurrence of liver toxicity

For patients with liver toxicity, pazopanib C_{trough} prior to the occurrence of liver toxicity (median 37 days) was available from 21/25 patients (84%). For patients without liver toxicity, the pazopanib C_{trough} was available from 98/108 (91%) patients. The median number of available pazopanib C_{trough} levels was 1 (range 0–2).

The average pazopanib C_{trough} (median (IQR)) prior to occurrence of liver toxicity was 27.7 (23.5–38.6) mg/L for patients with liver toxicity compared to 28.1 (21.1–34.6) mg/L for patients without liver toxicity ($P = 0.335$). Pazopanib C_{trough} at the moment of occurrence of liver toxicity was available from 22/25 patients (88%) (30.3 (23.5–41.9) mg/L) and did not differ from average pazopanib concentration in patients without liver toxicity ($P = 0.146$). The average pazopanib C_{trough} for each individual patient is shown in Fig. 1.

Logistic regression analysis demonstrated a significant association between the occurrence of $ALT > 5 \times ULN$ and average pazopanib C_{trough} , with an odds ratio (OR) of 1.064 (95% confidence interval 1.010–1.122). Though the average pazopanib C_{trough} in patients with $ALT > 5 \times ULN$ was similar to patients with $ALT < 5 \times ULN$ (27.7 (21.3–34.6) mg/L versus 31.3 (25.0–43.5) mg/L; $P = 0.136$).

Logistic regression analysis demonstrated no statistically significant associations between the occurrence of liver toxicity and patients' age, BMI, performance status, tumor type, pre-treatment, pazopanib exposure, statin or acetaminophen use.

Management and follow-up of liver toxicity

The management and follow-up of patients with pazopanib-induced liver toxicity is shown in Fig. 2.

Of the 7 patients with $ALT/AST 3–5 \times ULN$, 6 patients continued pazopanib without treatment interruption. The dose was increased in 1 patient (due to a low pazopanib C_{trough} of 15.9 mg/L), decreased in 1 patient (due to a high C_{trough} of 64.2 mg/L) and continued without dose alteration in 4 patients. In 1 patient pazopanib was interrupted and restarted after treatment with corticosteroids.

Of the 4 patients with $ALT/AST 5–8 \times ULN$, 1 permanently discontinued pazopanib treatment due to PD. In the remaining 3 patients, pazopanib was interrupted and restarted after treatment with corticosteroids.

Of the 14 patients with $ALT/AST > 8 \times ULN$, pazopanib was either continued without treatment interruption ($n = 1$, no dose alteration), restarted after treatment interruption ($n = 7$) or permanently discontinued ($n = 6$). Five of 7 patients who restarted pazopanib after treatment interruption were treated with corticosteroids for liver toxicity. In

Table 1 Baseline characteristics

	No liver toxicity (N=108)	Liver toxicity (N=25)	Overall (N=133)
Age in years	63 (23–85)	61 (31–80)	62 (23–85)
Gender			
Female	35 (32.4)	9 (36.0)	44 (33.1)
Male	73 (67.6)	16 (64.0)	89 (66.9)
BMI	26.1 (17.2–43.8)	27.4 (19.5–36.7)	26.4 (17.2–43.8)
Karnofsky Performance Score	80 (50–100)	80 (60–100)	80 (50–100)
Type of tumor			
RCC	82 (75.9)	16 (64.0)	98 (73.7)
STS	24 (22.2)	9 (36.0)	33 (24.8)
Other ^a	2 (1.9)	0 (0.0)	2 (1.5)
IMDC risk classification (RCC)			
Favorable	12 (14.6)	4 (25.0)	16 (16.3)
Intermediate	48 (58.5)	10 (62.5)	58 (59.2)
Poor	20 (24.4)	2 (12.5)	22 (22.4)
Unknown	2 (2.4)	0 (0.0)	2 (2.0)
Presence of liver metastases ^b			
Yes	21 (19.6)	6 (24.0)	27 (20.5)
No	86 (80.4)	19 (76.0)	105 (79.5)
Pretreatment with systemic therapy			
Yes	52 (48.1)	12 (48.0)	64 (48.1)
No	56 (51.9)	13 (52.0)	69 (51.9)
Starting dose pazopanib			
800 mg without food	71 (65.7)	20 (80.0)	91 (68.4)
600 mg with food	15 (13.9)	0 (0.0)	15 (11.3)
600 mg without food	6 (5.6)	2 (8.0)	8 (6.0)
400 mg with food	3 (2.8)	0 (0.0)	3 (2.3)
400 mg without food	13 (12.0)	2 (8.0)	15 (11.3)
200 mg without food	0 (0.0)	1 (4.0)	1 (0.8)
Laboratory investigations			
Hemoglobin (mmol/l)	7.5 (4.3–10.3)	8.1 (5.0–9.7)	7.5 (4.3–10.3)
White blood cells (*10 ⁹ /l)	7.3 (3.3–16.2)	7.0 (4.0–67.8)	7.2 (3.3–67.8)
Thrombocytes (*10 ⁹ /l)	270 (38–787)	242 (134–685)	263 (38–787)
Neutrophils (*10 ⁹ /l)	5.0 (1.7–15.0)	4.7 (2.4–8.8)	4.8 (1.7–15.0)
Calcium (mmol/l)	2.4 (1.6–3.1)	2.4 (2.3–2.6)	2.4 (1.6–3.1)
Creatinine (umol/l)	89 (40–355)	98 (55–216)	90 (40–355)
ALT (IU/l)	22 (9–106)	23 (16–64)	23 (9–106)
AST (IU/l)	23 (9–82)	24 (16–62)	24 (9–82)
LDH (IU/l)	212 (118–687)	197 (120–878)	209 (118–878)
GGT (IU/l)	49 (11–650)	40 (14–364)	47 (11–650)
ALP (IU/l)	101 (41–587)	88 (47–271)	97 (41–587)
Bilirubin, total (umol/l)	6 (3–22)	6 (4–13)	6 (3–22)
Bilirubin, direct (umol/l)	3 (2–16)	2 (2–6)	2 (2–16)
Albumin (g/l)*	33 (19–43)	37 (19–42)	34 (19–43)
Use of statin ^b			
Yes	19 (17.8)	6 (24.0)	25 (18.9)
No	88 (82.2)	19 (76.0)	107 (81.1)
Use of acetaminophen ^b			
Yes	80 (74.8)	17 (68.0)	97 (73.5)
No	27 (25.2)	8 (32.0)	35 (26.5)

Continuous variables are presented as median (range) and categorical variables as *n* (%), unless otherwise specified

ALP Alkaline phosphatase, *ALT* alanine transaminase, *AST* aspartate transaminase, *GGT* gamma-glutamyl transferase, *LDH* lactate dehydrogenase

*Statistically significant

^aOne patient had ovarian cancer and one patient had endometrial cancer

^bData were missing for one patient

Fig. 1 Average pazopanib concentration for individual patients in relation to ALT level. Scatter plot of the average pazopanib C_{trough} prior to the occurrence of liver toxicity in relation to ALT level for both males (dots) and females (crosses) ($n = 119$ patients). The vertical dotted grey lines represent the $3 \times ULN$ for both males (right) and females (left). The average pazopanib C_{trough} was calculated over 8 weeks prior to the occurrence of liver toxicity for patients with liver toxicity and over 8 weeks until the median time to liver toxicity for patients without liver toxicity. ALT alanine transaminase





Fig. 2 Management of liver toxicity in study cohort. Management of liver toxicity, including whether pazopanib was rechallenged or permanently discontinued when liver toxicity occurred. Reasons for permanent discontinuation without attempting to rechallenge were PD

($n = 1$), death due to a combination of PD and liver toxicity ($n = 1$), ALT/AST $> 8 \times ULN$ combined with a bilirubin level $> 2 \times ULN$ ($n = 2$) and switch to another line of treatment due to liver toxicity ($n = 3$). PD progressive disease; TKI tyrosine kinase inhibitor

the 6 patients who permanently discontinued pazopanib, 5 patients received treatment with corticosteroids. Reasons for permanent discontinuation were ALT/AST $> 8 \times ULN$

combined with a bilirubin level $> 2 \times ULN$ ($n = 2$), death ($n = 1$; due to a combination of PD and liver toxicity) and switch to another line of treatment ($n = 3$; 2 patients switched

to sunitinib and 1 to everolimus). Management of individual patients with pazopanib-induced liver toxicity is shown in Supplemental Table 1.

In total, 18 out of 25 patients (72%) continued/restarted pazopanib treatment after occurrence of liver toxicity. Pazopanib could be successfully continued in 16/18 patients (89%) for a prolonged period (median 231 days (66–1282) in RCC and 200 days (50–990) in STS). The pazopanib dose after the occurrence of liver toxicity compared to the dose when liver toxicity occurred is shown in Table 2. Half of the patients were able to safely continue pazopanib after liver toxicity at the same dose as before the occurrence of liver toxicity. Average pazopanib C_{trough} after the occurrence of liver toxicity was 28.9 (21.0–47.4) mg/L. All patients who continued/restarted pazopanib treatment had adequate pazopanib C_{trough} (> 20.5 mg/L). Nine of 18 patients (50%) received treatment with corticosteroids, either due to lack of recovery of ALT ($n=4$), recurrence of liver toxicity after restart of pazopanib ($n=2$) or simultaneously with pazopanib restart ($n=3$). Patients who started corticosteroids had higher ALT levels compared to patients without treatment with corticosteroids (median (IQR) 385 (247–452) IU/L versus 151 (122–361) IU/L; $P=0.08$).

Of all the patients with liver toxicity, 23 patients (92%) showed recovery of liver toxicity. One of the patients in whom there was no recovery died due to a combination of rapid disease progression and liver failure (probably due to extensive liver metastases) and 1 patient was lost to follow-up. Median time until recovery of liver toxicity was 21 (7–105) days.

Based on the observations made in this study and the recommendations listed in the drug label an expert

opinion-based algorithm was developed for the management of pazopanib-induced liver toxicity (Table 3). The first step in the algorithm is the evaluation of ALT and bilirubin level. The second step is the evaluation of pazopanib C_{trough} at the occurrence of liver toxicity. Based on the clinical data several recommendation steps are incorporated thereafter.

Association between occurrence of liver toxicity and survival

The median (range) duration of follow-up for patients with or without liver toxicity was 20.6 (1.5–76.7) and 17.1 (1.0–85.6) months, respectively. For both RCC and STS, no statistically significant difference in both PFS and OS was observed between patients with or without liver toxicity (Supplemental Figs. 1 and 2).

Discussion

In this retrospective observational cohort study, we investigated pazopanib-induced liver toxicity in real-world patients and developed a practical expert opinion-based algorithm for the management of pazopanib-induced liver toxicity, defined as ALT and/or AST > 3 × ULN (or > 3 × BLN). Pazopanib exposure was comparable in patients with or without liver toxicity. Continuation of pazopanib was attempted in 18/25 patients and successful in 16/18 patients. A total of 9/18 patients were able to safely continue pazopanib at the same dose as before the occurrence of liver toxicity. In total, 16 out of 25 patients were able to safely continue or resume pazopanib treatment despite liver toxicity.

This is the first study describing the association between pazopanib exposure and the occurrence of liver toxicity in real-world patients. In this real-world population, we investigated possible factors that are known to predispose individuals for DILI. Furthermore, we developed a practical algorithm to guide clinicians in the management of pazopanib-induced liver toxicity. In our study, approximately 20% of patients developed liver toxicity according to the definition in the drug label and similar to the percentages reported in the registration trials [1, 2]. We found no significant difference in average pazopanib C_{trough} between patients with or without liver toxicity. In contrast, Suttle et al. described that the incidence of ALT elevations increased with increasing pazopanib C_{trough} [22]. However, Noda et al. showed in a small study ($n=27$), that pazopanib exposure was not significantly associated with grade ≥ 2 ALT elevation [29]. We did find an increased probability of ALT > 5 × ULN with increasing pazopanib steady state C_{trough} , according to the FDA pharmacology review, with an OR of 1.064 which we consider not clinically relevant [3].

Table 2 Dosing patterns in patients experiencing liver toxicity

Change in dose at pazopanib continuation or restart	Number of patients (%)
Continued at the same dose	9 (50)
800 mg fasted	6 (33)
600 mg with food	2 (11)
600 mg fasted	1 (6)
Decrease in dose	8 (44)
1 dose level	7 (39)
600 mg with food	1 (6)
600 mg fasted	4 (22)
200 mg with food	1 (6)
200 mg fasted	1 (6)
2 dose levels	1 (6)
400 mg fasted	1 (6)
Increase in dose (1 dose level)	1 (6)
800 mg with food	1 (6)

Table 3 Algorithm to treat liver toxicity based on laboratory investigation and measured pazopanib exposure

Laboratory investigation	Pazopanib concentration	Recommendation–step 1	Recommendation–step 2	Recommendation–step 3	Recommendation–step 4	Recommendation for pazopanib dose at restart or continuation ^b
ALT > 3 × ULN + bili > 2 × ULN	–	Stop pazopanib	No recovery ^a → interrupt pazopanib until recovery	No recovery ^a /recurrence → corticosteroids	No recovery ^a /recurrence → stop pazopanib	No dose adjustment
ALT 3–5 × ULN	< 30 mg/L	Continue pazopanib + weekly monitoring liver enzymes				
ALT 3–5 × ULN	≥ 30 mg/L	Continue pazopanib + weekly monitoring liver enzymes	No recovery ^a → interrupt pazopanib until recovery	No recovery ^a /recurrence → corticosteroids	No recovery ^a /recurrence → stop pazopanib	Consider – 1 dose level ^c
ALT > 5 × ULN	< 30 mg/L	Interrupt pazopanib until recovery	No recovery ^a /recurrence → corticosteroids	No recovery ^a /recurrence → stop pazopanib		No dose adjustment
ALT > 5 × ULN	≥ 30 mg/L	Interrupt pazopanib until recovery	No recovery ^a /recurrence → corticosteroids	No recovery ^a /recurrence → stop pazopanib		Consider – 1 dose level ^c
Recommended corticosteroids schedule						
Dose corticosteroids						
Week 1						Prednisolone 30 mg OD
Week 2 + 3						Prednisolone 15 mg OD
Week 4 + 5 (if ALT < 3 × ULN)						Prednisolone 10 mg OD
Week 6 + 7 (if ALT persistently < 3 × ULN)						Prednisolone 5 mg OD
After week 7						Stop prednisolone
Dose levels of pazopanib						
Pazopanib dose fasted ^d						
Dose level						Pazopanib dose with food ^e
– 3			200 mg OD fasted			–
– 2			400 mg OD fasted			200 mg OD with food
– 1			600 mg OD fasted			400 mg OD with food
0			800 mg OD fasted ^f			600 mg OD with food ^f
1			400 mg BID fasted			800 mg OD with food

ALT Alanine transaminase, ULN upper limit of normal, ALT alanine transaminase, OD once a day, ULN upper limit of normal, BID twice a day, OD once a day

^aRecovery is defined as ALT < 3 × ULN

^bDose recommendations apply to every step

^c– 1 dose level refers to a – 1 level dose reduction, regardless of the initial dose level

^dDrug label pazopanib [10]

^eLubberman et al. [21]

^fBioequivalent dose

Pazopanib-induced liver toxicity is a treatment-limiting toxicity that can have important clinical implications, especially in patients with STS for whom treatment options are limited [30, 31]. The recommendations for the management of pazopanib-induced liver toxicity according to the drug label are limited to either interrupting or permanently discontinuing pazopanib treatment and, if possible, restarting pazopanib at a reduced dose [10]. This study clearly demonstrates the wide variety in the management of liver toxicity in real-world practice. Therefore, the recommendations in the drug label were combined with the observations in this study and translated into an expert opinion-based treatment algorithm for pazopanib-induced liver toxicity. For patients with a combination of $ALT > 3 \times ULN$ and bilirubin level $> 2 \times ULN$ pazopanib should be permanently discontinued [10]. For patients with $ALT 3\text{--}8 \times ULN$ the label recommends to continue pazopanib with weekly monitoring of ALT levels, and for patients with $ALT > 8 \times ULN$ to interrupt pazopanib. However, most medical oncologists are accustomed to use CTCAE grading to score and assess toxicity in clinical practice, in which a grade 2 ALT elevation is defined as $ALT 3\text{--}5 \times ULN$ and a grade 3 as $ALT 5\text{--}20 \times ULN$ [32]. Therefore, the cut-off of $ALT > 5 \times ULN$ was incorporated into the algorithm. In case treatment is interrupted, the drug label recommends to restart pazopanib at a reduced dose of 400 mg OD (50%). Since the limited relationship between pazopanib exposure and the occurrence of liver toxicity shown here, this advice is questionable, especially since pazopanib exposure has been related to PFS in mRCC [22, 33]. Therefore, patients with pazopanib-induced liver toxicity should maintain adequate pazopanib exposure for the remaining part of their treatment. To prevent unnecessary dose reductions leading to subtherapeutic exposure and thereby lack of efficacy, measurement of pazopanib C_{trough} at occurrence of liver toxicity was incorporated into the algorithm. A dose reduction should only be considered in patients with higher pazopanib C_{trough} . A threshold for pazopanib exposure of > 30 mg/L was incorporated into the algorithm, based on the fact that a dose reduction at this concentration with 25–33% will still result in pazopanib exposure > 20.5 mg/L, which is in line with the observation in the current study that all patients who continued/restarted pazopanib treatment had adequate pazopanib C_{trough} (> 20.5 mg/L), regardless of the dose they received. Recovery of liver toxicity was defined as a decline in $ALT < 3 \times ULN$. The definition of no recovery was at the discretion of the treating physician, however it concerned patients with a very slow decline, plateau or even rise in ALT level. Based on our experience in routine practice, we recommend to start treatment with prednisolone 30 mg OD in patients without recovery of ALT ($3 \times ULN$) after interruption of pazopanib or patients with recurrence of ALT elevations after restart of pazopanib [18, 20]. The rationale

behind corticosteroids is that pazopanib-induced liver toxicity might be immune mediated, as has been described for imatinib [34]. In immune-mediated DILI it is believed that drug metabolites activate the immune system and CD8 T lymphocytes [35]. It could have been interesting to investigate human leukocyte antigen (HLA) alleles, since HLA-B*57:01 carriage has been associated with liver toxicity [19]. However, due to the retrospective character of this study, it is not possible anymore to retrieve these data.

A remarkable finding in this study was that none of the 18 patients who started pazopanib intake with food developed liver toxicity. Patient numbers are small and there are no reports in literature describing this phenomenon for pazopanib or other hepatotoxic drugs. Further observations are needed to conclude if this food effect is relevant, and if it is, what the mechanism would be.

In the current study, although patient numbers were small, it appeared from the exploratory analyses that PFS and OS were not worse for patients with liver toxicity, neither predictive for efficacy, as is, for example, the onset of pazopanib-induced hand-foot syndrome in patients with STS [36].

Some factors are known to predispose individuals for DILI, such as obesity or pre-existing liver disease (including the presence of liver metastases) [37, 38]. A relationship between these factors and the occurrence of liver toxicity could not be confirmed in the current study, possibly due to small patient numbers. There might be other risk factors for the occurrence of liver toxicity, however, due to the limited number of patients in this study a selection of covariates was made to be included in the logistic regression analysis. Acetaminophen use was investigated as a possible covariate as well. However, acetaminophen is available as over-the-counter medication and may be used by patients without reporting it to their physician. As a limitation of a retrospective study, this was not documented explicitly in the patient files and could possibly have biased the results. However, since acetaminophen-induced DILI is most often the result of supratherapeutic dosages, it is unlikely that this has affected our results [7]. Other laboratory abnormalities apart from ALT, AST and bilirubin have been associated with liver toxicity as well, such as gamma-glutamyl transferase [39]. However, based on the drug label, ALT, AST and bilirubin were investigated in this study. Since this was an observational cohort study including real-world patients, the interruption of pazopanib or initiation of corticosteroids was performed on the initiative of the treating physician. Therefore, it is uncertain whether recovery of liver toxicity was the result of treatment with corticosteroids or part of the natural course of the disease. Finally, we only included patients of whom at least one pazopanib trough level was available. Especially during the first part of this study period, measurement of pazopanib C_{trough} was not yet

incorporated into routine care and was especially used in patients experiencing adverse events or lacking efficacy of treatment, which could have biased the results.

Conclusion

In this study, we did not find a relation between pazopanib exposure and the occurrence of liver toxicity. Our clinical experience based algorithm, based on dose alterations and treatment with corticosteroids, appears to be an effective strategy to treat pazopanib-induced liver toxicity, enabling patients who have shown to benefit from pazopanib, to continue this treatment safely.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00280-023-04615-7>.

Acknowledgements The authors thank M. van Egmond for the collection of data and setting up data-analysis.

Author contributions KW: concept and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. SK: concept and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. NS: interpretation of data, revising the manuscript, final approval of manuscript. WG: provision of study material or patients, interpretation of data, revising the manuscript, final approval of manuscript. ET: interpretation of data, revising the manuscript, final approval of manuscript. HW: provision of study material or patients, interpretation of data, revising the manuscript, final approval of manuscript. ID: concept and design, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript. NE: concept and design, provision of study material or patients, data analysis and interpretation, manuscript writing, final approval of manuscript.

Funding This study was part of the TUNE project (grant no. 11575) funded by the Dutch Cancer Society (KWF Kankerbestrijding).

Data availability The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations

Conflict of interest SK received speaker honoraria from GSK outside the submitted work. WG has been on advisory boards of SpringworksTx, PTC Therapeutics and Agenus, honoraria were paid to the institute; she has obtained a research grant from Eli Lilly (to the institute). NE received grants for the conduct of investigator driven studies from Ipsen and Astellas. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, Luszana. NS received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All

outside the submitted work, all payment to the Netherlands Cancer Institute. The other authors declare no potential conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol* 28(6):1061–1068. <https://doi.org/10.1200/JCO.2009.1023.9764>. (Epub 2010 Jan 1025)
2. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 379(9829):1879–1886. [https://doi.org/10.1016/S0140-6736\(1812\)60651-60655](https://doi.org/10.1016/S0140-6736(1812)60651-60655). (Epub 62012 May 60616)
3. US Food and Drug Administration, Center for Drug Evaluation and Research (2008, December 19) Pazopanib clinical pharmacology and biopharmaceutics review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf. Accessed 2 Nov 2023
4. Lee WM (2003) Drug-induced hepatotoxicity. *N Engl J Med* 349(5):474–485. <https://doi.org/10.1056/NEJMra021844>
5. Chang CY, Schiano TD (2007) Review article: drug hepatotoxicity. *Aliment Pharmacol Ther* 25(10):1135–1151. <https://doi.org/10.1111/j.1365-2036.2007.03307.x>
6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] (2012) Bethesda (MD): national institute of diabetes and digestive and kidney diseases. <https://www.ncbi.nlm.nih.gov/books/NBK547852/>. Accessed 2 Nov 2023
7. Rotundo L, Pyrsopoulos N (2020) Liver injury induced by paracetamol and challenges associated with intentional and unintentional use. *World J Hepatol* 12(4):125–136. <https://doi.org/10.4254/wjh.v12.i4.125>
8. Katarey D, Verma S (2016) Drug-induced liver injury. *Clin Med (Lond)* 16(Suppl 6):s104–s109. <https://doi.org/10.7861/clinmedicine.16-6-s104>
9. European Association for the Study of the Liver. Electronic address easloffice@easloffice.eu, Clinical Practice Guideline Panel Chair, Panel members, EASL Governing Board representative (2019) EASL clinical practice guidelines: drug-induced liver injury. *J Hepatol* 70(6):1222–1261. <https://doi.org/10.1016/j.jhep.2019.02.014>
10. GlaxoSmithKline (2021, September) Votrient (pazopanib) highlights of prescribing information. <https://www.accessdata.fda.gov/>

- [drugsatfda_docs/label/2021/022465s031s032lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022465s031s032lbl.pdf). Accessed 2 Nov 2023
11. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (2023) Pazopanib summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf. Accessed 2 Nov 2023
 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] (2012) Bethesda (MD): national institute of diabetes and digestive and kidney diseases; 2012-. Pazopanib. [Updated 2020 May 10]. <https://www.ncbi.nlm.nih.gov/books/NBK548110/>. Accessed 2 Nov 2023
 13. Wang YK, Yang XN, Liang WQ, Xiao Y, Zhao Q, Xiao XR, Gonzalez FJ, Li F (2019) A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. *Xenobiotica* 49(6):655–670. <https://doi.org/10.1080/00498254.2018.1489167>
 14. Paludetto MN, Stigliani JL, Robert A, Bernardes-Genisson V, Chatelut E, Puisset F, Arellano C (2020) Involvement of pazopanib and sunitinib aldehyde reactive metabolites in toxicity and drug-drug interactions in vitro and in patient samples. *Chem Res Toxicol* 33(1):181–190. <https://doi.org/10.1021/acs.chemrestox.9b00205>
 15. Saran C, Sundqvist L, Ho H, Niskanen J, Honkakoski P, Brouwer KLR (2022) Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors. *J Pharmacol Exp Ther* 380(2):114–125. <https://doi.org/10.1124/jpet.121.000828>
 16. Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN (2011) Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. *J Hepatol* 54(6):1237–1243. <https://doi.org/10.1016/j.jhep.2010.09.028>
 17. Henriksen JN, Bottger P, Hermansen CK, Ladefoged SA, Nissen PH, Hamilton-Dutoit S, Fink TL, Donskov F (2020) Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. *Clin Genitourin Cancer* 18(1):62–68 e62. <https://doi.org/10.1016/j.clgc.2019.09.013>
 18. Klemptner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D, Atkins MB (2012) Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. *J Clin Oncol* 30(27):e264–268. <https://doi.org/10.1200/JCO.2011.41.0332>
 19. Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN (2016) HLA-B 57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer. *Clin Cancer Res* 22(6):1371–1377. <https://doi.org/10.1158/1078-0432.CCR-1315-2044>. (Epub 2015 Nov 1376)
 20. Vletterie M, van Erp NP, van der Graaf WT (2015) Promising management of pazopanib-induced liver toxicity. *Acta Oncol* 54(7):1064–1066. <https://doi.org/10.3109/0284186X.2015.1004368>
 21. Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes D, van Herpen CML, van Erp NP (2019) The Effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study). *Clin Pharmacol Ther* 106(5):1076–1082. <https://doi.org/10.1002/cpt.1515>
 22. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. *Br J Cancer* 111(10):1909–1916. <https://doi.org/10.1038/bjc.2014.1503>. (Epub 2014 Oct 1928)
 23. Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N (2017) Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. *Cancer Chemother Pharmacol* 80(6):1171–1178. <https://doi.org/10.1007/s00280-00017-03463-x>. (Epub 2017 Oct 00219)
 24. Minot-This MS, Boudou-Rouquette P, Jouinot A, de Percin S, Balakirouchenane D, Khoudour N, Tlemsani C, Chauvin J, Thomas-Schoemann A, Goldwasser F, Blanchet B, Alexandre J (2022) Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients. *Pharmaceutics* 14(6):1224. <https://doi.org/10.3390/pharmaceutics14061224>
 25. Lin Y, Ball HA, Suttle B, Mehmud F, Amado RG, Hutson TE, Pandite LN (2011) Relationship between plasma pazopanib concentration and incidence of adverse events in renal cell carcinoma. *J Clin Oncol* 29(7_suppl):345–345. https://doi.org/10.1200/jco.2011.29.7_suppl.345
 26. Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR (2015) Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. *J Oncol Pract* 11(6):491–497. <https://doi.org/10.1200/JOP.2015.004929>. (Epub 2015 Sep 004921)
 27. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. *Ther Drug Monit* 31(5):579–584. <https://doi.org/10.1097/FTD.1090b1013e3181b1092c1098cf>
 28. van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ, Hartigh J (2013) A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 937:33–43. <https://doi.org/10.1016/j.jchromb.2013.1008.1013>. (Epub 2013 Aug 1017)
 29. Noda S, Yoshida T, Hira D, Murai R, Tomita K, Tsuru T, Kagayama S, Kawauchi A, Ikeda Y, Morita SY, Terada T (2018) Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma. *Clin Genitourin Cancer* 7(18):30734–30731
 30. de Juan FA, Alvarez Alvarez R, Casado Herraes A, Cruz Jurado J, Estival Gonzalez A, Martin-Broto J, Martinez Marin V, Moreno Vega A, Sebio Garcia A, Valverde Morales C (2021) SEOM clinical guideline of management of soft-tissue sarcoma (2020). *Clin Transl Oncol* 23(5):922–930. <https://doi.org/10.1007/s12094-020-02534-0>
 31. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee J, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Alava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S, Esmo Guidelines Committee E, clinicalguidelines@esmo.org GEa (2021) Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(☆). *Ann Oncol* 32(11):1348–1365. <https://doi.org/10.1016/j.annonc.2021.07.006>
 32. Institute NC (2017) Common terminology criteria for adverse events (CTCAE). <https://ctep.cancer.gov/protocoldevelopment/>

- [electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf](#). Accessed 2 Nov 2023
33. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. *Clin Cancer Res* 15(12):4220–4227. <https://doi.org/10.1158/1078-0432.CCR-4208-2740>. (Epub 2009 Jun 4229)
 34. Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A, Aglietta M (2009) An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. *Am J Clin Oncol* 32(6):640–641. <https://doi.org/10.1097/COC.0b013e31802b4ef7>
 35. Czaja AJ (2011) Drug-induced autoimmune-like hepatitis. *Dig Dis Sci* 56(4):958–976. <https://doi.org/10.1007/s10620-011-1611-4>
 36. Huang PW, Chou WC, Shen WC, Hung CY, Huang KG, Su YL, Lu CH, Liu CT, Chang YS, Liau CT (2018) Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: a multicenter study in the Asian population. *Asia Pac J Clin Oncol* 14(4):353–360. <https://doi.org/10.1111/ajco.13029>
 37. Li X, Tang J, Mao Y (2022) Incidence and risk factors of drug-induced liver injury. *Liver Int* 42(9):1999–2014. <https://doi.org/10.1111/liv.15262>
 38. Davern TJ (2012) Drug-induced liver disease. *Clin Liver Dis* 16(2):231–245. <https://doi.org/10.1016/j.cld.2012.03.002>
 39. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Clinical Course and Diagnosis of Drug Induced Liver Disease. [Updated 2019 May 4]. <https://www.ncbi.nlm.nih.gov/books/NBK548733/>. Accessed 2 Nov 2023

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.